Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia.
C Y
CY
Cheah
D A
DA
Carney
S M
SM
Lim
H
H
Januszewicz
J
J
Scarlett
J F
JF
Seymour
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20 / Q000276:immunology*; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D017707:Erythrocyte Transfusion; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology; D008218:Lymphocytosis / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; C527517:ofatumumab